Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor.author | SILVA, NICOLAS FRANCISCO | - |
Autor(es): dc.contributor.author | SOUSA, NATALIA BARRETO DE | - |
Data de aceite: dc.date.accessioned | 2024-05-08T06:33:14Z | - |
Data de disponibilização: dc.date.available | 2024-05-08T06:33:14Z | - |
Data de envio: dc.date.issued | 2024-05-07 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/746226 | - |
Resumo: dc.description.abstract | Omalizumab is a humanized monoclonal antibody used to treat allergic conditions, such as moderate to severe allergic asthma and chronic spontaneous urticaria. It specifically acts on immunoglobulin E (IgE), an important mediator of the allergic response. 245 articles were analyzed in the PubMed, LILACS and SciELO databases, resulting in 23 articles selected following inclusion and exclusion criteria. The included articles were published in the last 10 years and addressed the efficacy and clinical considerations of omalizumab in asthma and atopic dermatitis. Studies have demonstrated its effectiveness in controlling asthma, especially in severe and difficult-to-control cases, reducing exacerbations and improving quality of life. In children, omalizumab has been shown to be a promising therapeutic option for severe uncontrolled asthma, significantly reducing exacerbations and improving disease control. In addition to asthma, omalizumab has also been studied in atopic dermatitis, demonstrating a reduction in symptoms and an improvement in quality of life. However, its use is not free from side effects, such as reactions at the injection site and increased risk of respiratory infections, and it is important to carefully evaluate the benefits and risks for each patient. In conclusion, omalizumab represents a valuable therapeutic option for children and adolescents with severe allergic asthma and atopic dermatitis, offering an innovative approach to treating allergic conditions. | pt_BR |
Idioma: dc.language.iso | en | pt_BR |
Palavras-chave: dc.subject | OMALIZUMAB | pt_BR |
Título: dc.title | OMALIZUMAB IN CHILDREN OVER 12 YEARS OLD - EFFECTIVENESS AND CLINICAL CONSIDERATIONS IN ASTHMA AND ATOPIC DERMATITIS: A LITERATURE REVIEW (Atena Editora) | pt_BR |
Tipo de arquivo: dc.type | livro digital | pt_BR |
Aparece nas coleções: | Livros digitais |
Arquivos associados: | ||||
---|---|---|---|---|
omalizumabe-em-criancas-maiores-de-12-.pdf | 253,23 kB | Adobe PDF | /bitstream/capes/746226/1/omalizumabe-em-criancas-maiores-de-12-.pdfDownload |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: